Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q1 2025
    • Preferential Rights Issue Q1 2024
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. English
Key downloads
Alligator Bioscience AB reports financial results for Q2 2025 and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025Alligator Bioscience AB reports financial results for Q1 2025 and provides a business updateAlligator Bioscience publishes Annual Report for 2024Bulletin from the extraordinary general meeting in Alligator Bioscience AB
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2025-07-14

Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer

Lund, Sweden – 14 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...
Continue reading
2025-07-10
Regulatory

Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update

GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 ...
Continue reading
2025-07-01

Alligator to present 24-month OPTIMIZE-1 data at ESMO GI 2025

Lund, Sweden, 1 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical- ...
Continue reading
2025-06-30
Regulatory

Change in number of shares and votes in Alligator Bioscience AB

During June 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result o ...
Continue reading
2025-06-17

Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab

Lund, Sweden, 17 June 2025 — Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-d ...
Continue reading
2025-06-13

Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer

Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Continue reading
2025-06-03

Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting

Lund, Sweden, 3 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that biomarker data from its OPTIMIZE-1 cli ...
Continue reading
2025-05-26
Regulatory

Alligator Bioscience AB carries out directed issues to guarantors in connection with exercise of warrants series TO 12

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Continue reading
2025-05-262025-05-28

Alligator Bioscience announces Henlius receives European orphan drug designation for HLX22 in gastric cancer

Lund, Sweden – 26 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Commission has granted orphan ...
Continue reading

Posts navigation

Older posts
  1. Startpage
  2. News
  3. English
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all